These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors. Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590 [TBL] [Abstract][Full Text] [Related]
3. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Flechner SM; Kobashigawa J; Klintmalm G Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899 [TBL] [Abstract][Full Text] [Related]
4. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis. Lin M; Mittal S; Sahebjam F; Rana A; Sood GK Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27862340 [TBL] [Abstract][Full Text] [Related]
5. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Tönshoff B; Höcker B Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497 [TBL] [Abstract][Full Text] [Related]
6. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B; Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318 [TBL] [Abstract][Full Text] [Related]
7. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy. Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189 [TBL] [Abstract][Full Text] [Related]
8. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology. Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152 [TBL] [Abstract][Full Text] [Related]
9. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial. Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715 [TBL] [Abstract][Full Text] [Related]
10. Calcineurin Inhibitor Free De Novo Immunosuppression in Liver Transplant Recipients With Pretransplant Renal Impairment: Results of a Pilot Study (PATRON07). Schnitzbauer AA; Sothmann J; Baier L; Bein T; Geissler EK; Scherer MN; Schlitt HJ Transplantation; 2015 Dec; 99(12):2565-75. PubMed ID: 26018348 [TBL] [Abstract][Full Text] [Related]
11. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study. Gustafsson F; Andreassen AK; Andersson B; Eiskjær H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L; Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292 [TBL] [Abstract][Full Text] [Related]
12. Deferred pre-emptive switch from calcineurin inhibitor to sirolimus leads to improvement in GFR and expansion of T regulatory cell population: a randomized, controlled trial. Bansal D; Yadav AK; Kumar V; Minz M; Sakhuja V; Jha V PLoS One; 2013; 8(10):e75591. PubMed ID: 24146762 [TBL] [Abstract][Full Text] [Related]
13. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study. Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776 [TBL] [Abstract][Full Text] [Related]
14. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study. Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006 [TBL] [Abstract][Full Text] [Related]
15. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation. Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219 [TBL] [Abstract][Full Text] [Related]
16. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results. Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373 [TBL] [Abstract][Full Text] [Related]
17. A randomized, prospective comparison of transition to sirolimus-based CNI-minimization or withdrawal in African American kidney transplant recipients. Fleming JN; Taber DJ; Pilch NA; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD; Bratton CF Clin Transplant; 2016 May; 30(5):528-33. PubMed ID: 26914542 [TBL] [Abstract][Full Text] [Related]